Department of Gastroenterological Surgery, the First Affiliated Hospital of Chongqing Medical University, Chongqing 400042, P.R. China.
Department of Gastroenterological Surgery, Yong chuan Hospital of Chongqing Medical University, Chongqing 400016, P.R. China.
Biosci Rep. 2020 Mar 27;40(3). doi: 10.1042/BSR20194342.
Metastasis and chemoresistance indicate treatment fail and progresses in gastric cancer (GC) patients. However, the molecular mechanisms of chemoresistance and metastasis remain unclear in GC. Thus, identifying the biological indicators of chemoresistance and metastasis is particularly important.
We establish a role for miR-492 in GC metastasis and chemoresistance through experiments in vitro and in vivo.
We identified miR-492 overexpression in GC specimens and cell lines, the miR-492 expression level was inversely correlated with the prognosis of GC patients. The inhibition of miR-492 suppressed GC cell invasion and enhanced the sensitivity of gastric cancer cells to CDDP treatment. In contrast, miR-492 overexpression significantly stimulated GC cell invasion and contributed to chemoresistance development. In addition, our research results indicated that the inhibition of miR-492 stimulates GC stemness, and the overexpression of miR-492 induces GC stemness. Importantly, our experiments demonstrated that miR-492 inhibitor suppressed tumor formation, and the combination treatment of miR-492 inhibitor and CDDP significantly inhibited tumor growth in vivo. Furthermore, we demonstrated that miR-492 exerts its anticancer role by targeting DNMT3B in GC.
Our results suggested that inhibiting miR-492 is a novel strategy to control tumor metastasis and chemoresistance in GC.
转移和化疗耐药性表明胃癌(GC)患者的治疗失败和进展。然而,GC 中化疗耐药性和转移的分子机制仍不清楚。因此,确定化疗耐药性和转移的生物学标志物尤为重要。
我们通过体外和体内实验确定了 miR-492 在 GC 转移和化疗耐药中的作用。
我们发现 miR-492 在 GC 标本和细胞系中过度表达,miR-492 的表达水平与 GC 患者的预后呈负相关。抑制 miR-492 抑制 GC 细胞侵袭并增强胃癌细胞对 CDDP 治疗的敏感性。相反,miR-492 的过表达显著刺激 GC 细胞侵袭并促进化疗耐药的发展。此外,我们的研究结果表明,抑制 miR-492 刺激 GC 干性,而过表达 miR-492 诱导 GC 干性。重要的是,我们的实验表明,miR-492 抑制剂抑制肿瘤形成,miR-492 抑制剂和 CDDP 的联合治疗显著抑制体内肿瘤生长。此外,我们证明 miR-492 通过靶向 GC 中的 DNMT3B 发挥其抗癌作用。
我们的结果表明,抑制 miR-492 是控制 GC 肿瘤转移和化疗耐药性的一种新策略。